Matches in Wikidata for { <http://www.wikidata.org/entity/Q64108177> ?p ?o ?g. }
- Q64108177 description "article" @default.
- Q64108177 description "im Januar 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q64108177 description "wetenschappelijk artikel" @default.
- Q64108177 description "наукова стаття, опублікована у 2019" @default.
- Q64108177 name "APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy" @default.
- Q64108177 name "APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy" @default.
- Q64108177 type Item @default.
- Q64108177 label "APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy" @default.
- Q64108177 label "APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy" @default.
- Q64108177 prefLabel "APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy" @default.
- Q64108177 prefLabel "APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy" @default.
- Q64108177 P1433 Q64108177-1B349329-F0E8-40D5-9FDC-9350CE4EF988 @default.
- Q64108177 P1476 Q64108177-C01AA1E0-5FF8-4880-93E8-C9FE0A52018C @default.
- Q64108177 P2093 Q64108177-5A324999-87FF-47E3-A29A-2151B272A693 @default.
- Q64108177 P2093 Q64108177-5BD51196-238C-4C76-9E6C-169AB578D8E3 @default.
- Q64108177 P2093 Q64108177-9AA4F153-2CA2-4F95-BE55-84DC83D0D0CA @default.
- Q64108177 P2093 Q64108177-AA6C5AE2-B99C-4CFD-AFD9-8DABDAD0309D @default.
- Q64108177 P2093 Q64108177-E4380E8D-4DBF-4621-A50A-8F321C7A4882 @default.
- Q64108177 P2093 Q64108177-F68A4DDF-4853-4127-80E6-6EE80E89F61C @default.
- Q64108177 P275 Q64108177-3a42f082-c6a5-47ca-83f4-e58d66fb7673 @default.
- Q64108177 P2860 Q64108177-01D370CA-0DD2-4628-B8F2-5D16525EB292 @default.
- Q64108177 P2860 Q64108177-13DA5FD7-AEB4-4401-9C25-CB7481B98F50 @default.
- Q64108177 P2860 Q64108177-19596575-7BD3-4E30-9F55-B5D2324CF934 @default.
- Q64108177 P2860 Q64108177-1A7837FB-0129-4650-BD1B-7B9E7D6FAA8F @default.
- Q64108177 P2860 Q64108177-223E50A5-D6A8-4EBA-B97E-DDF5A890F6DC @default.
- Q64108177 P2860 Q64108177-22616535-6035-4FD9-B249-25C926C7462F @default.
- Q64108177 P2860 Q64108177-2395D45B-719E-4743-A2D4-44E30B3CBD7D @default.
- Q64108177 P2860 Q64108177-25F0A4B6-3AC4-4A02-BD32-2F93D4F4031D @default.
- Q64108177 P2860 Q64108177-2B134F73-804E-4AAD-9E12-7AD982CCD2B4 @default.
- Q64108177 P2860 Q64108177-2F2C5BDD-5CD1-4ABE-B77D-0E159EFB9AE3 @default.
- Q64108177 P2860 Q64108177-2FCAAD04-A630-476C-A5B2-70D6A2A7BF3F @default.
- Q64108177 P2860 Q64108177-313FD591-E129-46E0-A6A1-947D709FCA3D @default.
- Q64108177 P2860 Q64108177-3A4C3FB5-FC5F-44F8-BA1D-D56CA261717F @default.
- Q64108177 P2860 Q64108177-3A7C016F-136E-4587-BAB4-B7FE3B24EFD6 @default.
- Q64108177 P2860 Q64108177-3D35413C-4BF8-4D0C-B659-D09E5A7499D4 @default.
- Q64108177 P2860 Q64108177-5915EBDF-96AB-4173-B684-69C52E50B08B @default.
- Q64108177 P2860 Q64108177-5AF6F370-D6A8-40F6-A343-1A76B388149C @default.
- Q64108177 P2860 Q64108177-6107CAF5-1B3A-434C-B03C-4D713D90E184 @default.
- Q64108177 P2860 Q64108177-648F7685-0B1A-42BD-AAC6-6A963FB62C6B @default.
- Q64108177 P2860 Q64108177-6EDD0E47-8FC6-4B85-A40C-5D371E571440 @default.
- Q64108177 P2860 Q64108177-7174C2F4-E00D-4734-9580-FDC3153ECA07 @default.
- Q64108177 P2860 Q64108177-89603133-6212-4FA5-A1AD-84C00240B8C9 @default.
- Q64108177 P2860 Q64108177-8DDD9492-1FF2-4614-8239-F0D03953225A @default.
- Q64108177 P2860 Q64108177-8F16FBFB-1981-44AE-B7AF-63F653F23BD2 @default.
- Q64108177 P2860 Q64108177-9916F540-430F-497B-AB3B-4A87AB96CED1 @default.
- Q64108177 P2860 Q64108177-D343A49F-FDD1-4C63-9A26-70003A98B9AC @default.
- Q64108177 P2860 Q64108177-DBF951EC-B0BD-4781-9E5E-71033007A6BA @default.
- Q64108177 P2860 Q64108177-E5EB5056-8BE7-4F69-BC52-CF771011EE50 @default.
- Q64108177 P2860 Q64108177-F3FCCD15-B9C7-47E7-A079-8818FFBADD61 @default.
- Q64108177 P2860 Q64108177-F8C89205-00A4-4667-83CC-3D0DA5BB8DEF @default.
- Q64108177 P2860 Q64108177-FA01D954-4104-46B9-8DFA-78E04B2BF43B @default.
- Q64108177 P2860 Q64108177-FDD2BB44-A800-44C3-8304-F1123BAD4630 @default.
- Q64108177 P304 Q64108177-30B9F8C4-C315-43BA-92C6-56C4C852079E @default.
- Q64108177 P31 Q64108177-9A33199A-BB9B-4C4B-945D-872C60ADFA86 @default.
- Q64108177 P356 Q64108177-63449458-CA63-4DFD-B3F2-C973E9BFDF11 @default.
- Q64108177 P407 Q64108177-835D3555-FE16-42DA-B9DE-13384F7BA55A @default.
- Q64108177 P478 Q64108177-1A0C4F75-0238-44E2-9F60-E6464537A3CB @default.
- Q64108177 P577 Q64108177-1C6B2AF3-9B4B-468B-AC3A-F7D3F0BC2D31 @default.
- Q64108177 P6216 Q64108177-f4779f06-18c0-4056-8434-8c60841aa307 @default.
- Q64108177 P698 Q64108177-61B0F620-C31C-4068-9F01-C715F6E9E70F @default.
- Q64108177 P921 Q64108177-5FD40E05-C60F-43B9-BA17-18E78FDD9960 @default.
- Q64108177 P921 Q64108177-69300C39-FA5E-477B-9115-901DE0CCB19B @default.
- Q64108177 P921 Q64108177-A61F1EB6-06CE-4B75-829C-68F5F4A6522A @default.
- Q64108177 P921 Q64108177-AD4B1FD8-B99E-4492-AE7A-E3B12D1295BD @default.
- Q64108177 P932 Q64108177-7A63226D-C50E-423C-BF59-B50954B3AB98 @default.
- Q64108177 P356 JPR.S171013 @default.
- Q64108177 P698 30881102 @default.
- Q64108177 P1433 Q6295704 @default.
- Q64108177 P1476 "APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy" @default.
- Q64108177 P2093 "David A Burt" @default.
- Q64108177 P2093 "David G Soergel" @default.
- Q64108177 P2093 "Emily Cook" @default.
- Q64108177 P2093 "Eugene R Viscusi" @default.
- Q64108177 P2093 "Franck Skobieranda" @default.
- Q64108177 P2093 "Neil Singla" @default.
- Q64108177 P275 Q18810331 @default.
- Q64108177 P2860 Q26331003 @default.
- Q64108177 P2860 Q28504554 @default.
- Q64108177 P2860 Q28590279 @default.
- Q64108177 P2860 Q30611776 @default.
- Q64108177 P2860 Q33552207 @default.
- Q64108177 P2860 Q34321618 @default.
- Q64108177 P2860 Q34326054 @default.
- Q64108177 P2860 Q34373083 @default.
- Q64108177 P2860 Q35213193 @default.
- Q64108177 P2860 Q35586363 @default.
- Q64108177 P2860 Q35935385 @default.
- Q64108177 P2860 Q36646115 @default.
- Q64108177 P2860 Q36974487 @default.
- Q64108177 P2860 Q37149936 @default.
- Q64108177 P2860 Q37926697 @default.
- Q64108177 P2860 Q37992281 @default.
- Q64108177 P2860 Q38764697 @default.
- Q64108177 P2860 Q39179065 @default.
- Q64108177 P2860 Q39345979 @default.
- Q64108177 P2860 Q40229666 @default.
- Q64108177 P2860 Q41688726 @default.
- Q64108177 P2860 Q42705103 @default.
- Q64108177 P2860 Q44762023 @default.
- Q64108177 P2860 Q46510708 @default.